Italian medtech directorate relocates
This article was originally published in Clinica
Executive Summary
Italy's general directorate for pharmaceuticals and medical devices has been relocated, in a move that brings all health ministry departments, other general directorates and the national healthcare council under one roof (except the minister's office itself, which remains at Lungotevere Ripa 1). The new headquarters feature updated and more efficient systems which, the ministry claims, will provide a better service to all "healthcare operators" and members of the public. The new address, in the Eur area on the outskirts of the city, is: Via Giorgio Ribotta 5, 00144 Roma, Italy.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.